Mimetogen Pharmaceuticals receives series A financing

McGill Univ spinoff Mimetogen Pharmaceuticals Inc has received series A financing from a venture capital consortium led by Boston-based VIMAC Milestone Medica Fund. Also participating is original investor MSBi Capital, a seed and early-stage fund created to commercialize technologies from McGill, Univ of Sherbrooke and Bishop's Univ. Mimetogen is currently developing therapeutic approaches for small cell lung cancer and glaucoma. Its technology is based on 10 years of R&D at McGill and its affiliated Lady Davis Institute for Medical Research. Mimetogen recently appointed Dr Garth Cumberlidge as its president and CEO....